Scientists and physicians can better assess precision genome editing technology using a new method made public today by St.

CHANGE-seq-BE was developed to enable scientists to better understand base editors, an important class of CRISPR precise genome editors.

GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology startup focusing on genome-editing therapeutic solutions, today announced that the U.S. Food and Drug Administration (FDA) has cleared ...

Find how Circularization for High-throughput Analysis of Nuclease Genome-wide Effects by Sequencing Base Editors ...

A new CRISPR breakthrough shows scientists can turn genes back on without cutting DNA, by removing chemical tags that act ...

Scientists have developed a novel approach of genome editing to repair muscle stem (satellite) cells, offering new hope for ...

The US Food and Drug Administration (FDA) has cleared GenEditBio Limited’s Investigational New Drug (IND) application to ...

Restricted access to genome-editing technologies poses serious challenges for countries like India that urgently need such ...

In a few decades, gene-editing technologies could reduce the likelihood of common human diseases. Societies must use this time to prepare for their arrival. Read the paper: Heritable polygenic editing ...

A dire wolf de-extinction debate, CRISPR-GPT for gene editing, and more topped the list of our most popular stories in ...

GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology startup focusing on genome-editing therapeutic solutions, today announced that the U.S.